Outlook Therapeutics
OTLK
75 hedge funds and large institutions have $29.6M invested in Outlook Therapeutics in 2022 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 24 increasing their positions, 19 reducing their positions, and 9 closing their positions.
26% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 19
1% more capital invested
Capital invested by funds: $29.3M → $29.6M (+$350K)
0.08% more ownership
Funds ownership: 0.53% → 0.61% (+0.08%)
0% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 9
1% less funds holding
Funds holding: 76 → 75 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Altium Capital Management
New York
|
+$3.62M |
| 2 |
BlackRock
New York
|
+$206K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$120K |
| 4 |
Goldman Sachs
New York
|
+$101K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$60.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$164K |
| 2 |
Two Sigma Advisers
New York
|
-$160K |
| 3 |
VF
Vista Finance
Clayton,
Missouri
|
-$130K |
| 4 |
Renaissance Technologies
New York
|
-$61K |
| 5 |
GL
Graypoint LLC
Albany,
New York
|
-$46K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
76
Renaissance Technologies
New York
| – | -$61K | -2,515 | Closed |
|
|
GL
77
Graypoint LLC
Albany,
New York
| – | -$46K | -1,875 | Closed |
|
78
Squarepoint
New York
| – | -$39K | -1,605 | Closed |
|
79
SG Americas Securities
New York
| – | -$30K | -1,246 | Closed |
|
80
William Blair & Company
Chicago,
Illinois
| – | -$28K | -1,150 | Closed |
|
|
KW
81
KWB Wealth
Redlands,
California
| – | -$20K | -820 | Closed |
|
82
D.E. Shaw & Co
New York
| – | -$13K | -530 | Closed |
|
83
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| – | -$12K | -500 | Closed |
|
OTLK Hedge Fund Activity: Q4 2022 in Review
75 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics (OTLK) for Q4 2022, worth a combined $29.6M — up 1.2% from $29.3M a quarter earlier.
Fund positioning in OTLK was balanced in Q4 2022: 9 funds opened new positions, 9 closed out, 24 added to existing stakes and 19 trimmed.
The largest buyer was Altium Capital Management, opening a new position worth an estimated $3.62M. The largest seller was Fidelity Investments, cutting an estimated $164K.
- 75 institutional investors held Outlook Therapeutics (OTLK) as of Q4 2022, down from 76 in Q3 2022.
- Funds reported $29.6M of Outlook Therapeutics stock for Q4 2022, up 1.2% quarter-over-quarter.
- 9 funds opened new Outlook Therapeutics positions in Q4 2022 and 9 closed out, a net change of 0 holders.
- The largest Outlook Therapeutics buyer in Q4 2022 was Altium Capital Management, an estimated $3.62M added.
- The largest Outlook Therapeutics seller in Q4 2022 was Fidelity Investments, an estimated $164K sold.
Based on aggregated 13F filings for Q4 2022.